Dr. Charles M Farber, MD
Claim this profileMorristown Medical Center
Area of expertise
Lung Cancer
Charles M Farber, MD has run 5 trials for Lung Cancer. Some of their research focus areas include:
Lymphoma
Charles M Farber, MD has run 5 trials for Lymphoma. Some of their research focus areas include:
Affiliated Hospitals
Morristown Medical Center
Overlook Hospital
Clinical Trials Charles M Farber, MD is currently running
Combination Therapy
for Multiple Myeloma
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Recruiting
2 awards
Phase 3
32 criteria
LP-300 + Chemotherapy
for Lung Adenocarcinoma EGFR
This trial tests a new drug, LP-300, combined with two existing chemotherapy drugs in never smokers with a specific type of lung cancer who did not respond to previous treatments. The goal is to see if this combination improves survival by making the chemotherapy more effective.
Recruiting
3 awards
Phase 2
4 criteria
More about Charles M Farber, MD
Clinical Trial Related
13 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Charles M Farber, MD has experience with
- Pembrolizumab
- Brentuximab Vedotin
- Carboplatin
- Pemetrexed
- Nivolumab
- Dacarbazine
Breakdown of trials Charles M Farber, MD has run
Lung Cancer
Lymphoma
Non-Small Cell Lung Cancer
Hodgkin's Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Charles M Farber, MD specialize in?
Charles M Farber, MD focuses on Lung Cancer and Lymphoma. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Charles M Farber, MD currently recruiting for clinical trials?
Yes, Charles M Farber, MD is currently recruiting for 2 clinical trials in Morristown New Jersey. If you're interested in participating, you should apply.
Are there any treatments that Charles M Farber, MD has studied deeply?
Yes, Charles M Farber, MD has studied treatments such as Pembrolizumab, Brentuximab Vedotin, Carboplatin.
What is the best way to schedule an appointment with Charles M Farber, MD?
Apply for one of the trials that Charles M Farber, MD is conducting.
What is the office address of Charles M Farber, MD?
The office of Charles M Farber, MD is located at: Morristown Medical Center, Morristown, New Jersey 07960 United States. This is the address for their practice at the Morristown Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.